Chang Shu

Prof. Dr. Chang Shu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2025 in Analytical Chemistry
Verified
Journal Article
Open access
JNJiangyue Ning
Jiangyue Ning
XBXingyan Bao
Xingyan Bao
HCHaotian Chen
Haotian Chen
ZYZelong Yan
Zelong Yan
LDLi Ding
Li Ding
CSChang Shu
Chang Shu
Trypsin is a specific and reliable diagnostic biomarker of pancreatic function and pathological changes. Thus, detecting trypsin and screening trypsin inhibitors are highly important for clinical diagnosis and disease treatment. Herein, we propose a colorimetric/fluorescence sensing probe based on carbon quantum dots (O-CDs) and cytochrome C (Cyt C) for sensitive and specific trypsin detection and trypsin inhibitor screening. The prepared O-CDs exhibit a persistent fluorescence and environmental tolerance. In the presence of trypsin, Cyt C is hydrolyzed into a heme with oxidase mimetic activity that can convert colorless TMB into blue oxTMB, which strongly absorbs at 652 nm and quenches the fluorescence of the O-CDs at 580 nm via the inner filter effect. This sensing probe realizes the precise determination of trypsin with a wide linear range (10-2000 ng/mL in both colorimetric and fluorescence modes) and a low limit of detection (0.05 ng/mL in colorimetric mode and 3.44 ng/mL in fluorescence mode). The developed method was then applied to detect trypsin in human serum and urine with good accuracy and reproducibility. Furthermore, the sensing probe was successfully applied to screen trypsin inhibitors from legumes on the basis of their ability to inhibit the trypsin activity. Thus, this dual-mode detection method has great potential for clinical application in the diagnosis of trypsin-related diseases, as well as for screening trypsin inhibitor drugs.

14 March 2018 in Royal Society Open Science
Verified
Journal Article
Open access
CSChang Shu
Chang Shu
TLTengfei Li
Tengfei Li
WYWen Yang
Wen Yang
DLDuo Li
Duo Li
SJShunli Ji
Shunli Ji
LDLi Ding
Li Ding
The present work is focused on the design and development of novel amphotericin B (AmB)-conjugated biocompatible and biodegradable polypeptide hydrogels to improve the antifungal activity. Using three kinds of promoting self-assembly groups (2-naphthalene acetic acid (Nap), naproxen (Npx) and dexamethasone (Dex)) and polypeptide sequence (Phe-Phe-Asp-Lys-Tyr, FFDKY), we successfully synthesized the Nap-FFDK(AmB)Y gels, Npx-FFDK(AmB)Y gels and Dex-FFDK(AmB)Y gels. The AmB-conjugated hydrogelators are highly soluble in different aqueous solutions. The cryo-transmission electron microscopy and scanning electron microscopy micrographs of hydrogels afford nanofibres with a width of 20–50 nm. Powder X-ray diffraction analyses demonstrate that the crystalline structures of the AmB and Dex are changed into amorphous structures after the formation of hydrogels. Circular dichroism spectra of the solution of blank carriers and the corresponding drug deliveries further help elucidate the molecular arrangement in gel phase, indicating the existence of turn features. The in vitro drug releases suggest that the AmB-conjugated hydrogels are suitable as drug-controlled release vehicles for hydrophobic drugs. The antifungal effect of AmB-conjugated hydrogels significantly exhibits the antifungal activity against Candida albicans . The results of the present study indicated that the AmB-conjugated hydrogels are suitable carriers for poorly water soluble drugs and for enhancement of therapeutic efficacy of antifungal drugs.

19 January 2023 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
SLSuiyi Liu
Suiyi Liu
SWShuang Wang
Shuang Wang
YZYazhen Zhao
Yazhen Zhao
JLJuan Li
Juan Li
CSChang Shu
Chang Shu
YHYuhui Hao
Yuhui Hao

11 January 2023 in RSC Advances
Verified
Journal Article
Open access
PDF file
PHPenghui Hu
Penghui Hu
RHRuiyan Huang
Ruiyan Huang
YXYe Xu
Ye Xu
TLTengfei Li
Tengfei Li
JYJun Yin
Jun Yin
CSChang Shu
Chang Shu
Schematic representation of ALP activity detection based on a ratiometric fluorescent biosensor in biological samples via an inner-filter effect.

1 April 2021 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
QXQinhan Xu
Qinhan Xu
CSChang Shu
Chang Shu
YLYachao Li
Yachao Li
RZRong Zhuang
Rong Zhuang
LJLei Jiang
Lei Jiang
XXXianghui Xu
Xianghui Xu
A new type of molecular and supramolecular strategy is proposed to controllably construct mixed-charged nanoparticles with resistance to protein adsorption.

18 April 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YLYuan Liang
Yuan Liang
YYYu Yang
Yu Yang
RHRuiyan Huang
Ruiyan Huang
JNJiangyue Ning
Jiangyue Ning
XBXingyan Bao
Xingyan Bao
CSChang Shu
Chang Shu
Depression ranks as the fourth most prevalent global disease, with suicide incidents occurring at a younger age. Sulpiride (SUL), an atypical antidepressant drug acting as a dopamine D2 receptor antagonist and possessing anti-inflammatory properties, exhibits limited ability to penetrate the blood brain barrier (BBB). This weak penetration hampers its inhibitory effect on prolactin release in the pituitary gland, consequently leading to hyperprolactinemia. In order to enhance the central nervous system efficacy of sulpiride and reduce serum prolactin levels, we covalently linked sulpiride to VPALR derived from the nuclear DNA repair protein ku70. In vivo study on depressive mice using intraperitoneal injection of VPALR-SUL demonstrated a significant increase in struggle time and total distance compared to those treated with only sulpiride while also reducing serum prolactin concentration. The pharmacokinetic study results showed that VPALR-SUL prolonged half-life and increased bioavailability. In conclusion, VPALR-SUL exhibited potential for enhancing sulpiride transport across the BBB, augmenting its antidepressant effects, and reducing serum prolactin levels. This study laid a foundation for improving sulpiride delivery and developing novel antidepressants.